Peregrine Moncreiffe of that Ilk

PDMR Notification & Director Shareholding

Retrieved on: 
Tuesday, November 7, 2023
Peregrine Moncreiffe of that Ilk, Holding company

The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 60,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 2nd November 2023 at a price of £1.1469 per share.

Key Points: 

The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 60,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 2nd November 2023 at a price of £1.1469 per share.

PDMR Notification & Director Shareholding

Retrieved on: 
Tuesday, November 7, 2023
Peregrine Moncreiffe of that Ilk, Holding company

The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 40,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 3rd November 2023 at a price of £1.15 per share.

Key Points: 

The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 40,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 3rd November 2023 at a price of £1.15 per share.

Director/PDMR Shareholding

Retrieved on: 
Monday, February 13, 2023
Peregrine Moncreiffe of that Ilk, Security (finance)

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 200,000 Ordinary shares of 0.001 pence each in the Company (“Shares”) on 06 February 2023 at a price of 108.5 pence per share.

Board Change

Retrieved on: 
Thursday, February 2, 2023
Biotechnology, LSE, Peregrine Moncreiffe of that Ilk, Security (finance)

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • London, 26 January 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, today announces Dr Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests.
  • Peregrine Moncreiffe, Chairman of Arix, commented: “On behalf of the Board, I would like to thank Benny for the support he has shown to the Company since joining the Board last year and wish him well in his future endeavours.”

Director/PDMR Shareholding

Retrieved on: 
Friday, October 28, 2022
Company, Peregrine Moncreiffe of that Ilk, Security (finance)

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 50,000 Ordinary shares of 0.001 pence each in the Company (Shares) on 26 October 2022 at a price of 1.04 pence per share and a further purchase of 25,000 shares at a price of 1.04 pence per share on 27 October 2022.

Director/PDMR Shareholding

Retrieved on: 
Wednesday, October 5, 2022
Company, Peregrine Moncreiffe of that Ilk, Security (finance)

Dissemination of a Regulatory Announcement, transmitted by EQS Group.

Key Points: 
  • Dissemination of a Regulatory Announcement, transmitted by EQS Group.
  • The issuer is solely responsible for the content of this announcement.
  • The Company has been notified that Peregrine Moncreiffe, Director and Chairman of the Company purchased 100,000 Ordinary shares of 0.001 pence each in the Company (Shares) on 4 October 2022 at a price of 102.94 pence per Share.

Arix Bioscience plc Announces Changes to Board of Directors

Retrieved on: 
Wednesday, August 10, 2022
Destiny, Internal medicine, Senior, Liverpool, List of professional associations in the United Kingdom, Board, Durham University Business School, Weill Cornell Medicine, Compliance, Liverpool John Moores University, Roche, Therapy, Chartered Institute of Management Accountants, Yale New Haven Hospital, LSE, Knoll, Biotechnology, CureVac, NJCAA National Football Championship, GlaxoSmithKline, UK Corporate Governance Code, Virology, MBA, Master of Science, Yale University, MD, Management accounting, Pharmaceutical medicine, Emory University, Medical degree, Entrepreneurship, Peregrine Moncreiffe of that Ilk, Management, Immunology, Medicine, Novartis

Dr Debra Barker appointed as Senior Independent Director, replacing Sir Michael Bunbury

Key Points: 
  • Dr Debra Barker appointed as Senior Independent Director, replacing Sir Michael Bunbury
    LONDON, 10 August 2022: Arix Bioscience plc (Arix or the Company) (LSE: ARIX), is pleased to announce the appointments of Dr Debra Barker, Dr Benny Soffer, and Andrew Smith as Senior Independent Director and Non-Executive Directors respectively with immediate effect.
  • In light of these appointments which bring the Board into compliance with the UK Corporate Governance Code, Sir Michael Bunbury is resigning from the Board with immediate effect.
  • Debra is currently Non-Executive Director of three publicly listed biotechnology companies: Destiny Pharma plc, BergenBio in Norway and most recently, CureVac AG in Germany.
  • Peregrine Moncreiffe, Chairman of the Board of Arix, said: We are delighted to welcome Debra, Benny and Andrew to the Board.

Board Changes

Retrieved on: 
Wednesday, October 6, 2021
Foreign, Investment, Investment trust, Buckmaster & Moore, Patient, Buckmaster, Board, Senior, HarbourVest Global Private Equity, Company, LSE, Audit committee, Foreign & Colonial Investment Trust, Partner, Peregrine Moncreiffe of that Ilk, Smith & Williamson, Industry, Security (finance), Management

Sir Michael Bunbury will join the Board as Senior Independent Director, effective today.

Key Points: 
  • Sir Michael Bunbury will join the Board as Senior Independent Director, effective today.
  • Giles Kerr, Non-Executive Director and Chair of the Board's Audit Committee, will step down from the Board on 15 October 2021, after four years of service.
  • Together with the Board, I am pleased that Rob will continue in this role on a permanent basis and we look forward to continuing to work together.
  • We are also delighted to welcome Sir Michael Bunbury to the Arix Board.